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Abstract
 
Long-lasting tumor immunity requires functional mobilization of CD8
 
 
 
 and CD4
 
 
 
 T lympho-
cytes. CD4
 
 
 
 T cell activation is enhanced by presentation of shed tumor antigens by professional
antigen-presenting cells (APCs), coupled with display of similar antigenic epitopes by major
histocompatibility complex class II on malignant cells. APCs readily processed and presented
several self-antigens, yet T cell responses to these proteins were absent or reduced in the con-
text of class II
 
 
 
 melanomas. T cell recognition of select exogenous and endogenous epitopes
was dependent on tumor cell expression of 
 
 
 
-interferon–inducible lysosomal thiol reductase
(GILT). The absence of GILT in melanomas altered antigen processing and the hierarchy of im-
munodominant epitope presentation. Mass spectral analysis also revealed GILT’s ability to reduce
cysteinylated epitopes. Such disparities in the profile of antigenic epitopes displayed by tumors
and bystander APCs may contribute to tumor cell survival in the face of immunological defenses.
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Introduction
 
Establishment of long-term immunity to block tumor re-
currence depends upon the recruitment and activation of
both cytotoxic and helper T cells (1, 2). Tumors such as
melanomas can constitutively express both MHC class I
and II molecules, necessary for tumor antigen presentation
to T cells (3, 4). Yet, T cell priming and the development
of strong memory responses to tumor epitopes also appears
to require processing and cross-presentation of shed tumor
antigens via bystander professional APCs (5). The abundant
expression of adhesion and costimulatory molecules on
APCs such as dendritic cells, macrophages, and B lympho-
cytes, facilitates prolonged T cell receptor engagement by
MHC–ligand complexes and cellular activation (6). In addi-
tion, professional APCs appear to have evolved specialized
pathways to enhance antigen uptake and processing for
MHC-restricted presentation (7, 8). Once T cells are
primed, immunological recognition and tumor destruction
may be dependent upon the presentation of similar tumor-
derived peptides bound to MHC molecules on both malig-
nant cells and bystander APCs. Immunohistochemical
analyses of malignant human melanomas reveals 38–90% of
these tumors express class II DR (9, 10). Although less effi-
cient than professional APCs, these tumors can activate an-
tigen-specific CD4
 
 
 
 T cells (11, 12, 13). In the case of
MHC class II molecules, intracellular antigen processing
within acidic endosomes and lysosomes gives rise to a mul-
titude of peptides for display. Yet among these only a lim-
 
ited subset of epitopes, termed immunodominant are se-
lected for display by class II molecules and prove capable of
inducing strong T cell responses (14). The events which
shape epitope selection and immunodominance remain
poorly defined, yet clearly processing reactions within
 
APCs are of central importance (15–18). Thus, a critical
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issue remains as to whether malignant cells and professional
APCs share similar pathways for antigen processing and dis-
play identical profiles of tumor-derived peptides in the
context of MHC molecules for recognition by T cells.
To address this point, epitope processing and presenta-
tion were examined using professional APCs and class II
 
 
 
melanomas. Within professional APCs, processing reac-
tions such as proteolysis and disulfide reduction are highly
efficient and give rise to peptide ligands for MHC class II-
restricted presentation to T cells (7, 19–21). Little is
known concerning the efficiency of reductive processing
in tumors, thus we examined the ability of melanoma cells
to process and present a cysteinylated peptide, cys-
 
 
 
I de-
rived from the human antigen IgG 
 
 
 
 (18). Cysteinylation
of peptides and antigens occurs spontaneously in vivo and
in vitro via reaction with cystine in biological fluids (19,
22, 23). These oxidized molecules are endocytosed by
fluid phase and efficiently processed within professional
APCs before binding and functional class II–restricted pre-
sentation to CD4
 
 
 
 T cells (19). By contrast, we show here
that class II
 
 
 
 melanomas fail to process cysteinylated pep-
tides, resulting in the display of modified epitopes via tu-
mor cell MHC class II molecules and perturbations in
TCR recognition. A lysosomal thiol reductase, 
 
 
 
-IFN–
inducible lysosomal thiol reductase (GILT),
 
*
 
 abundantly
expressed by professional APCs, was absent or expressed
only at greatly reduced levels in human melanomas. Func-
tional studies in vivo and mass spectral analysis in vitro
demonstrated that reductive processing of cysteinylated
peptides was efficiently catalyzed by GILT. Thus, the ex-
pression of GILT in tumors could restore T cell recogni-
tion of oxidized epitopes. The lack of GILT in melanomas
also dramatically altered the processing of exogenous and
endogenous protein antigens, as assessed via the hierarchy
of antigenic peptides displayed by tumor cell class II mole-
cules. Thus, unlike professional APCs, tumor cells failed to
preferentially present an immunodominant epitope from
the antigen IgG to T cells. Transfection of melanomas
with GILT restored the presentation of this immunodomi-
nant IgG epitope as well as enhancing the presentation of a
distant antigenic epitope. Expression of GILT by tumors
also enhanced class II–restricted presentation of an endoge-
nous epitope derived from the melanoma antigen tyrosi-
nase. These studies demonstrate the importance of reduc-
tive processing within the class II pathway for antigen
presentation and immunodominant epitope selection. The
failure of melanomas to express GILT, a conserved enzyme
within the class II pathway, ultimately leads to tumor cell
display of an altered repertoire of MHC ligands. While
such differences may be exploited during the design of
immunotherapeutics, the display of modified antigenic
epitopes by tumors and professional APCs could also play a
role in the induction of immunological unresponsiveness
or tolerance.
 
Materials and Methods
 
Cell Lines.
 
APCs were cultured in IMDM with 10% heat-
inactivated calf serum, 50 U/ml penicillin, and 50 
 
 
 
g/ml strepto-
mycin. The human B-lymphoblastoid cell line, Frev constitu-
tively expresses cell surface class II 
 
  
 
 (DRB1
 
*
 
0401 allele).
Retroviral transduction was used to stably express the DR4w4
(DRB1
 
*
 
0401) allele in human monocytic cells (THP-1.DR4),
melanomas (J3.DR4, J3.GILT.DR4), and fibroblasts (M1.DR4)
with surface expression confirmed by cytofluorography using
the DR4-specific monoclonal antibody, 359F10 (24). Human
melanomas employed for this study include: J3 (DR
 
 
 
); SLM2-
mel (DR
 
 
 
; DRB1
 
*
 
0401); Colo-38 (DR
 
 
 
; DRB1
 
*
 
0401);
M1011(DR
 
 
 
); M1106(DR
 
 
 
); M21(DR
 
 
 
); M1259 (DR
 
 
 
); mel-
1174 (DR
 
 
 
); 1727A (DR
 
 
 
); mel-624 (DR
 
 
 
); SK-mel-19
(DR
 
 
 
); SK-mel-33 (DR
 
 
 
); and Vmm18 (DR
 
 
 
) provided by Dr.
W. Storkus (University of Pittsburgh, Pittsburgh, PA); mel-1359
(DR
 
 
 
; DRB1
 
*
 
0401) from Dr. S. Topalian (National Institutes of
Health-National Cancer Institute, Bethesda, MD); and SK-mel-
31 (DR
 
 
 
; DRB1
 
*
 
0401); and SK-mel-28 (DR
 
 
 
) from American
Type Culture Collection. Tumor cell DR expression was deter-
mined by FACS
 
®
 
 as well as immunoblotting, HLA typing and
functional assays were used to confirm HLA-DR4w4 allelic ex-
pression. For treatment of APCs with IFN-
 
 
 
, cells were cultured
in complete media in the presence of IFN-
 
 
 
 (50 U/ml; R&D
Systems) at 37
 
 
 
C for 48 h. T cell hybridomas specific for Ig 
 
 
 
peptides presented in the context of HLA-DR4, were generated
by immunization of DR4 (DRB1
 
*
 
0401)-transgenic mice with
human IgG. The hybridoma 2.18a recognizes Ig 
 
 
 
 peptide 188–
203 while the cell 1.21 responds to Ig 
 
 
 
 residues 145–159 (18). T
cell hybridomas and HT-2 cells were cultured in RPMI 1640
with 10% FBS, 50 U/ml penicillin, 50 
 
 
 
g/ml streptomycin, and
50 
 
 
 
M 
 
 
 
-mercaptoethanol. The threshold number of class II–
peptide complexes necessary to trigger each T cell line was com-
parable, as determined using titrating amounts of purified class II
antigens loaded with either 
 
 
 
 peptide (18). Thus, these T cells
provide a relative means to compare and quantitate the presenta-
tion of each 
 
 
 
 epitope by DR4 on distinct cell types.
 
Peptides.
 
The human IgG immunodominant (
 
 
 
I) peptide
 
 
 
188–203 (sequence KHKVYACEVTHQGLSS) and subdomi-
nant (
 
 
 
II) peptide 
 
 
 
145–159 (sequence KVQWKVDNALQS-
GNS) were produced by Fmoc technology and an Applied Bio-
systems Synthesizer with purity (
 
 
 
99%) and sequence assessed by
reverse phase HPLC and mass spectroscopy. Biotin-labeled pep-
tides were produced by the addition of biotin and 2 spacer mole-
cules of Fmoc-6-aminohexanoic acid at the amino termini, to
yield the sequence biotin-aminohexanoic acid-aminohexanoic
acid-peptide as confirmed by mass spectroscopy. Preparation of
purified cysteinylated 
 
 
 
I was achieved by reaction with cystine
followed by mass analysis to confirm the efficiency of modifica-
tion (19). Substituted forms of the 
 
 
 
I peptide were also generated
by Fmoc technology with Ala, Ser, or 2-amino-butyric acid re-
placing Cys 194 (19).
 
Generation of IgG-transfected Cell Lines.
 
The vector aLys27
and aLys38 encode cDNAs for hen egg lysozyme (HEL)-specific
human IgG 
 
 
 
 light chain and heavy chain respectively, provided
by Dr. Jefferson Foote, Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA (25). These heavy and light chain genes were
cotransfected into J3.DR4 and J3.GILT.DR4 by electroporation,
with stably transfected cells selected for vector-encoded drug re-
sistance genes. The resulting lines were subcloned and tested for
GILT expression by Western blotting. An ELISA procedure was
used to screen transfectants for anti-HEL Ig 
 
 
 
 production by im-
mobilization of HEL on ELISA plates followed by the addition of
 
*
 
Abbreviations used in this paper:
 
 aba, 2-aminobutyric acid; GILT, 
 
 
 
-IFN–
inducible lysosomal thiol reductase. 
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cell culture supernatants and detection of captured Ig using bi-
otin-labeled goat anti–human 
 
 
 
 F(ab
 
 
 
)
 
2
 
 horseradish peroxidase
(HRP)-streptavidin and ABTS. The transfectants J3.DR4-IgG
and J3.GILT.DR4-IgG produced equivalent amounts of IgG 
 
 
 
and class II DR4.
 
T Cell Proliferation Assays.
 
APCs or tumor cells were incu-
bated with synthetic 
 
 
 
 peptides or antigen for 3–24 h at 37
 
 
 
C in
culture media or HBSS, washed, and cocultured with T cell hy-
bridomas for 24 h. T cell cytokine production was monitored by
measuring [
 
3
 
H]thymidine incorporation using the IL-2/IL-4–
dependent cell line, HT-2. In some cases, APCs were prefixed
with 1% paraformaldehyde for 20 min on ice followed by wash-
ing and peptide addition, or post-fixed before coculture with T
cell hybridomas. Prefixation of cells under these conditions has
been shown to block endocytosis and intracellular antigen pro-
cessing (26). For IgG transfected tumors, cells (5 
 
  
 
10
 
3
 
) were
cocultured with either 2.18a or 1.21 T cells (10
 
4
 
) for 20–24 h at
37
 
 
 
C, and the production of cytokine was measured as described.
All assays were repeated at least three to four times with the stan-
dard error indicated.
 
Peptide Binding Assays.
 
Paraformaldehyde-fixed J3.DR4 and
J3.GILT.DR4 melanomas were incubated overnight with bio-
tinylated 
 
 
 
 peptides (
 
 
 
I and 
 
 
 
II) in HBSS, washed with PBS, and
lysed before capture of class II–peptide complexes with the anti-
body 37.1 (19). Quantitation of these complexes was achieved
using europium-labeled streptavidin and fluorimetry (18, 19).
 
Immunoblotting.
 
Cells were cultured with or without IFN-
 
 
 
(50 U/ml) for 48 h before Western blot analysis. For each cell
line, samples of 100 
 
 
 
g of total cell protein were fractionated by
SDS-PAGE followed by transfer to membranes and probing for
GILT expression using a rabbit antiserum, Vishnu, and chemilu-
minescence (27).
 
Enzymatic Assay of GILT Activity.
 
The purified cys-
 
 
 
I was
incubated in sodium acetate buffer (pH 4.5) with 400 
 
 
 
M cys-
teine 
 
 
 
/
 
 
 
 purified human GILT for 90 min at 37
 
 
 
C. The result-
ing samples were purified by passage through a ZipTip column
eluted with 50% acetonitrile (ACN) plus 0.1% TFA. Mass spec-
tral analysis was used to monitor changes in peptide mass (19).
Electrospray ionization was conducted with a spray voltage of 4.8
kV, a capillary voltage of 26 V, and a capillary temperature of
200
 
 
 
C. Spectra were scanned over a m/z range of 200 to 2,000.
Base peak ions were trapped using the quadruple ion trap and
further analyzed with a high resolution scan (zoom-scan) using an
isolation width of 3 m/z and collision-induced dissociation scans
with a collision energy of 40.0. For each sample tested, the ratio
of relative peak heights for ionized 
 
m
 
 
 
2
 
 fragments for the reduced
 
 
 
I (894 
 
m/z
 
) and cys-
 
 
 
I (954 
 
m/z
 
) peptides present in the reac-
tion mixture was calculated as an indication of epitope reduction.
 
Enzyme-linked Immunospot for IFN-
 
 
 
.
 
Tumor cell activation
of human T cells was monitored by IFN-
 
 
 
 secretion using en-
zyme-linked immunospot (ELISPOT) with spot numbers/sizes
determined using computer-assisted video image analysis (28).
Minimal cytokine production was detected using DR4
 
 
 
 APCs
which lack tyrosinase, while maximal T cell activation could be
achieved using APCs and synthetic antigenic peptides. T cell re-
sponses to endogenous melanoma antigens were quantitative, as
demonstrated using synthetic antigenic peptides and APCs. Hu-
man CD4
 
 
 
 T cells recognizing DR4 complexed with the tyrosi-
nase epitope 56–70 (QNILLSNAPLGPQFP), were derived from
melanoma patients (12, 29, 30). Specifically, CD4
 
 
 
 peripheral
blood T cells obtained from patients, were stimulated with pep-
tide-pulsed autologous dendritic cells followed by restimulations
with the appropriate peptide and autologous PBMCs (30). The
epitope and DR specificity of these T cells was established using
T2.DR4 cells and purified tyrosinase 56–70. DR4-restricted T
cells responsive to this epitope were observed in a majority of
melanoma patients after therapeutic intervention and tumor re-
gression (30). A CD8
 
 
 
 human T cell clone G209 which recog-
nizes HLA class I A2 and an epitope 209–217 from the endoge-
nous melanoma antigen gp100, was also tested (31).
 
Results
Melanoma Cells Fail to Present a Cysteinylated Peptide to
CD4  T Cells. T cells specific for complexes of the re-
duced  I peptide bound to DR4, recognized a cysteiny-
lated form of this epitope, cys- I only after processing and
presentation by a professional APCs, the human B-lym-
phoblastoid cell Frev (Fig. 1 A). Intracellular reduction or
processing of this cysteinylated peptide can be observed us-
ing a variety of APCs including B cells, dendritic cells, and
IFN- –induced macrophages (19). By contrast, class II 
melanoma cells (J3.DR4 and SLM2-MEL) failed to process
the cysteinylated peptide for T cell recognition (Fig. 1 A).
The class II molecules on these tumors efficiently bind pep-
tides such as  I (Fig. 1 B), suggesting these MHC mole-
cules are appropriately folded and functional. Despite the
lack of T cell responses to the cysteinylated  I, this oxi-
dized peptide bound preferentially to class II DR4 com-
pared with its reduced form. Additional studies revealed
that T lymphocyte activation could be detected using mel-
anomas and another class II–restricted peptide derived from
IgG termed  II, this epitope does not contain cysteine resi-
dues and is thus not susceptible to oxidative modification
(Fig. 1 A). Similar to the results with melanomas, a trans-
formed human fibroblast, M1.DR4 also failed to present
the cysteinylated  I peptide (Fig. 1 A).
Professional APCs and Melanomas Differ in Their Expression
of a Lysosomal Thiol Reductase, GILT. Cytokine treat-
ment of monocytes induces MHC class II expression as
well as cofactors necessary for efficient antigen presentation
such as HLA-DM and the invariant chain. Enhanced T cell
responses to cys- I could be detected in THP-1.DR4
monocytes after IFN-  treatment (Fig. 1 C). Cytokine ac-
tivation of the J3 melanoma also enhanced T cell responses
to the cys- I peptide by nearly fivefold (Fig. 1 C). T cell
responses to the cys- I could also be enhanced after IFN- 
treatment of additional DR4  melanomas, including the
tumors SLM2-mel and mel-1359 (data not shown). Yet,
the majority of the human melanomas examined including
J3 and SLM2-mel, constitutively express DR, DM, and in-
variant chain (data not shown), suggesting a deficiency in
these molecules was not responsible for failures in cystein-
ylated peptide presentation. In APCs, GILT has been
identified within endosomal and lysosomal compartments
containing MHC class II molecules (27). To determine
whether GILT expression correlated with functional pre-
sentation of cysteinylated epitopes, immunoblot analysis
was performed using human APCs, melanomas, and fibro-
blasts (Fig. 2 A). Professional APCs including B cells and
IFN-treated monocytes expressed abundant levels of GILT,1270 Alterations in Antigen Presentation due to the Lack of GILT in Melanomas
while melanomas and fibroblasts produced little if any re-
ductase. In a random survey of 16 melanomas,  80% of
these tumors were found to contain no immunoreactive
GILT (Table I). In the three tumors testing weakly positive
for this reductase, steady-state GILT levels were consis-
tently  20% that found constitutively in human B lym-
phoblasts. Analysis of only one tumor, SML2-MEL by im-
munoblotting revealed a slight increase ( 2,000 D) in the
migration of the reductase on SDS-PAGE. Differential gly-
cosylation of GILT has been observed previously among
cell lines, potentially providing an explanation for this mi-
nor shift in the reductase’s mass (32). IFN treatment of
melanomas induced GILT expression although reductase
levels were always significantly less than found in profes-
sional APCs. This result is consistent with our observation
that even after cytokine activation,  I epitope presentation
by J3.DR4 tumors was considerably less efficient compared
with IFN- –treated monocytes or B cells (Fig. 1 C).
In Vivo Requirement for GILT in Epitope Reduction. To
test the role of GILT in the presentation of cysteinylated
peptides, the J3 melanoma was transfected with human
GILT cDNA, and reductase expression detected by immu-
Figure 1. Failure of melanomas to process and present cysteinylated
peptides. (A) Functional analysis of class II–restricted presentation of  
peptides. T cells failed to recognize complexes of cys- I and HLA-DR4
displayed on human melanomas (J3.DR4, SLM2-mel), fibroblasts
(M1.DR4), and resting monocytes (THP-1.DR4). The B-lymphoblas-
toid cell, Frev, readily displayed functional complexes of class II and this
 I epitope. T cell responses were detected using each cell type and a dis-
tinct peptide,  II. Cells were incubated with 10  M peptide (cys- I or
 II) for 4 h at 37 C before incubation with T cells and detection of cy-
tokine production by HT-2 cell proliferation. (B) Binding of  I and cys-
 I to DR4 molecules on melanomas. Paraformaldehyde fixed J3.DR4
and J3.DR4.GILT cells were incubated overnight with biotin-labeled  I
or cys- I peptides in HBSS. Cells were washed, lysed, and the peptide
binding to captured DR4 molecules was quantitated using europium-labeled
streptavidin. Data are representative of mean fluorescence   SEM for at
least three separate experiments. (C) Cellular activation by IFN-  leads to
functional presentation of cys- I. THP-1.DR4 or J3.DR4 were cultured
with or without IFN-  (50 U/ml) for 48 h before incubation with
peptides. Cells were subsequently analyzed for their ability to activate
 -specific T cells. The relative percentage antigen presentation was calcu-
lated independently for each cell type by setting T cell responses with
IFN- –activated cells at 100. In this representative experiment, IFN- –
treated THP-1.DR4 cells were nearly fourfold more efficient in  I epitope
presentation compared with cytokine-activated tumors.
Figure 2. Reduced expression of GILT in melanomas is correlated
with a defect in the presentation of cysteinylated epitopes. (A) Determi-
nation of cellular GILT expression by Western immunoblotting. Tumor
cells and THP-1.DR4 monocytes were treated with IFN-  as in Fig. 1
C. For each sample, 100  g of total protein was analyzed from freshly
prepared cell lysates. As a standard, the relative electrophoretic mobility of
purified proteins of known molecular mass is indicated along side. (B)
Differential presentation of   peptides by J3.DR4 and J3.GILT.DR4
melanomas. Cells were incubated with   peptides (0–20  M) for 4 h at
37 C, before coculture with T cells and quantitation of cytokine produc-
tion. Results in A and B are representative of three separate analyses, with
the data listed as mean determinations for triplicate samples   standard error.1271 Haque et al.
noblotting (Fig. 2 A). Functional studies demonstrated that
in contrast with the parental tumor line, processing and
presentation of cys- I by J3.GILT.DR4 cells resulted in
measurable T cell activation (Fig. 2 B). Changes in GILT
expression did not influence  II peptide presentation by
melanomas. These experiments and flow cytometric analy-
sis (not shown), demonstrated that melanoma class II
expression and function remained unchanged following
GILT transfection. Mass spectroscopy confirmed the  I
peptide used for these studies was cysteinylated ( 95%) be-
fore incubation with tumor cells or APCs, suggesting only
GILT-expressing cells were able to efficiently catalyze
functional presentation of this epitope.
Delivery of cysteinylated epitopes to mature endocytic
compartments should be a prerequisite for reduction by
GILT. Transit of antigens or peptides from early to mature
endocytic compartments can be abrogated by culturing
cells at 18 C (19). Incubation of melanomas expressing
GILT with cys- I peptide at 18 C, completely blocked tu-
mor cell activation of  I peptide-specific T cells (Fig. 3 A).
Control studies demonstrated measurable T cell activation
in response to  II peptide presentation by melanoma cells
at this low temperature independent of GILT expression.
Direct measurements of peptide binding to class II DR4
also revealed measurable   epitope binding at 18 C (19). As
evidence that intracellular epitope reduction was key to
functional epitope presentation by GILT-transfected tu-
mors, T cell responses were examined using reduced and
cysteinylated forms of the  I peptide (Fig. 3, B and C). In-
cubation of aldehyde-fixed tumor cells with the reduced  I
peptide in a buffered solution, resulted in efficient T cell
activation. Similar results were obtained using tumors and
the  II peptide, or an analogue of  I containing 2-ami-
nobutyric acid (aba) as a substitute for cysteine at position
194. To induce cysteinylation of susceptible epitopes such
as  I, this same experiment was performed by culturing al-
dehyde-fixed tumors with peptides in the presence of cys-
tine. Under these conditions, T cell responses to the  I
epitope were ablated using tumor cells regardless of GILT
expression (Fig. 3 B). By contrast, similar assays performed
with the  I-aba or the  II peptide were minimally effected
by the addition of cystine during incubations with tumors
(Fig. 3 B). Aldehyde fixation blocks endocytosis and has
classically been used to inhibit intracellular antigen process-
ing. The failure of fixed tumor cells with or without GILT
to functionally present the cysteinylated  I peptide is there-
fore consistent with requirements for peptide internaliza-
tion and reduction. Maintenance of the  I peptide in a
reduced state using DTT, permitted nearly equivalent
epitope presentation by either J3.DR4 or J3.GILT.DR4
melanomas as monitored by T cell activation (Fig. 3 C).
Neither endocytosis nor processing of the reduced peptide
was required as demonstrated using aldehyde-fixed mela-
nomas (Fig. 3 B). Endocytic uptake of the cysteinylated
peptide appears to be a fluid phase process and is observed
in a wide variety of cell types (19). These results strongly
support a role for GILT in epitope reduction.
Investigations with APCs suggest that reduction of cys-
teinylated peptides may influence both binding to MHC as
well as TCR engagement (19, 21). In the case of the  I
peptide, binding to MHC is enhanced by cysteinylation yet
activation of TCR is completely disrupted (Fig. 1, B and
3). Furthermore, once bound to MHC class II molecules
the cysteinylated epitope is very resistant to reduction sug-
gesting these modified-peptide class II complexes reside on
the cell surface for a significant time (19). Experiments with
APCs failed to reveal any requirement for proteolytic pro-
cessing of the cys- I peptide, suggesting again that reduc-
tion of this peptide is key to T cell recognition (19). To
demonstrate that reductive cleavage of cys- I is the es-
sential step disrupted in melanomas lacking GILT, T cell
activation was examined using analogue  I peptides with
conservative cysteine substitutions of serine, alanine, or
2-aminobutyric acid (aba) at epitope position 194 (Fig. 3
D). Viable J3.DR4 cells incubated with the  I analogue
containing serine substituted for cysteine, failed to elicit any
T cell response (Fig. 3 D), consistent with earlier studies
demonstrating a failure of this peptide to engage TCR (19).
Alanine and aba substituted  I peptides were capable of
stimulating T cells in the context of live or fixed tumor
Table I. GILT Expression and DR4-restricted Epitope 
Presentation by Human Melanomas
T cell responsiveness
to DR4:   peptides
Cells GILT expression Cys- I  II
Frev                
J3        
J3.GILT               
SK-mel-31     
Colo-38     
SLM2-mel        
mel-1359        
M1011   ND ND
M1106   ND ND
M21   ND ND
mel-1259   ND ND
SK-mel-33   ND ND
1727A   ND ND
mel-1174   ND ND
mel-624   ND ND
SK-mel-19   ND ND
SK-mel-28   ND ND
Vmm 18   ND ND
Human melanomas were tested by immunoblotting for GILT
expression, and functional presentation of cys- I and  II peptides to T
cells as described in Materials and Methods. Data is expressed relative to
results obtained using the human B cell line, Frev. ND, not determined,
these cells do not express the appropriate DR4 allele.1272 Alterations in Antigen Presentation due to the Lack of GILT in Melanomas
cells independent of GILT expression (Fig. 3 D). Studies
using professional APCs also demonstrated that functional
presentation of the  I-aba analogue is not dependent on
endocytosis as assessed by cell fixation or low temperature
incubation (19). Thus, the requirement for GILT in func-
tional presentation of the  I epitope is linked to oxidative
modification of the peptide’s reactive cysteine.
Enzymatic Reduction of Cysteinylated Peptides by GILT.
Epitope reduction by GILT was directly demonstrated in
vitro using the cys- I peptide and ion spray mass spectrom-
etry (Fig. 4). Incubation of cys- I in the presence of a mild
reductant cysteine, failed to catalyze disulfide cleavage as
assessed by the ratio of reduced and oxidized peptide m 2
ion fragments at 894 and 954 m/z. By contrast, the addi-
tion of purified human GILT to this reaction mix resulted
in a linear increase in peptide reduction with cysteine act-
ing as the electron donor (Fig. 4, B and C). These results
demonstrate that GILT can function directly to reduce cys-
teinylated peptides.
Changes in the Hierarchy of Epitope Presentation Associated
with GILT Expression. The lack of GILT in melanomas
suggested that antigen processing and the hierarchy of
epitopes displayed by MHC class II molecules on these
cells might differ from professional APCs. B cells prefer-
entially generate and present functional DR4- I com-
plexes during human IgG processing (18; Fig. 5 C). Simi-
larly, analysis of T cell responses following immunization
of DR4 transgenic mice with human IgG, also revealed  I
epitope immunodominance in vivo (18). Cys 194 of the
 I peptide forms an intrachain disulfide within Ig kappa,
such that reduction of this bond may be important in
epitope selection and class II presentation. Processing and
presentation of human IgG by J3.DR4 tumors resulted in
only minimal display of the immunodominant epitope as
assessed by the activation of  I-specific T cells (Fig. 5 A).
A similar deficiency in functional presentation of the  I
epitope was observed using IgG and the tumor line, mel-
1359 (data not shown). However, each of these melanomas
retained the ability to generate and display a subdominant
epitope,  II in the context of class II DR4. Functional
class II–restricted presentation of the  I epitope was ob-
served with tumor cells expressing abundant GILT, re-
storing the preferential display of this immunodominant
epitope (Fig. 5 B). Enhanced presentation of the  II
epitope was also detected in GILT  cells, suggesting this
enzyme had a more global effect on antigen processing
and unfolding. The role of GILT in the preferential pre-
sentation of the  I epitope was also demonstrated in tu-
mor cells transfected to express endogenous Ig  antigen
(Fig. 5 D). Thus, the lack of GILT in tumors such as mel-
anomas can radically influence the hierarchy of epitopes
presented by class II molecules for T cell recognition.
The melanoma antigen, tyrosinase, contains multiple
cysteine residues and disulfide-linked domains (33). MHC
Figure 3. Endocytic transport
and reduction are essential for
functional presentation of cys-
teinylated epitopes. (A) Func-
tional presentation of cys- I in
cells expressing GILT was ab-
lated by disruption of peptide
sorting to late endosomes/lyso-
somes. J3.DR4 and J3.GILT.DR4
were incubated with   peptides
(10  M) at 18 C for 20 h. Cells
were subsequently aldehyde
fixed and incubated with T cells
at 37 C. The formation of  II
peptide-DR4 complexes on cells
was detected regardless of tem-
perature. (B) Disruption of cys-
 I processing by aldehyde fixa-
tion. Paraformaldehyde-fixed
J3.DR4 and J3.GILT.DR4 were
incubated 4 h with 10  M of ei-
ther purified  I,  II, or  I-aba
peptides in either HBSS or
HBSS   cystine (0.29 mM) to
promote epitope cysteinylation,
followed by coculture with T
cells. (C) Reduction of cys- I
overcomes the requirement for
epitope processing by GILT.
J3.DR4 and J3.GILT.DR4 cells
were incubated with   peptides
(10  M)   the reductant DTT
(0.2 mM) for 4 h at 37 C before
coculture with T cells and cytokine quantitation. (D) Melanomas present  I peptide variants resistant to cysteinylation. Tumor cells were incubated 4 h
at 37 C with peptides (10  M) before fixation and coculture with T cells. Peptides tested include cys- I, analogs of  I with Ala, Ser, or aba-substituted
for Cys at position 194, or  II. T cell responses to these  I analogs were identical using live or fixed tumors and independent of GILT expression.1273 Haque et al.
tide. Although the DR4-restricted tyrosinase epitope 56–
70 also lacks cysteine, within the native antigen a cysteine
position 55 is located just adjacent to this peptide. Whether
this cysteine is disulfide linked within tyrosinase remains
unclear, yet amino acids immediately adjacent to antigenic
epitopes have previously been shown to directly influence
processing and the hierarchy of presentation (35). Increased
flexibility or unfolding of protein domains after disulfide
reduction should enhance processing or MHC capture of
determinants, potentially accounting for the increase in T
cell activation observed using tumors with high GILT as
presenting cells.
Discussion
Unlike professional APCs, class II  melanoma cells ex-
press low steady-state levels of intracellular GILT within
their endosomal and lysosomal network. The absence of
GILT within these tumors resulted in deficiencies in the
processing and class II–restricted presentation of cystein-
ylated peptides, as well as changes in the selection of immu-
nodominant epitopes from both exogenous and endogenous
protein antigens rich in disulfide residues. By contrast, pro-
fessional APCs were proficient in reducing cysteinylated
peptides as well as antigens, thus influencing the hierarchy
of epitopes displayed in the context of class II molecules for
T cell recognition. While disulfide reduction may not be
Figure 4. In vitro reduction of cys- I by
GILT. (A) In the presence of a mild reductant,
cysteinylation of the  I epitope is maintained as
demonstrated by the detection of ionized spe-
cies at 954 and 636 m/z. The cys- I peptide
(calculated molecular mass 1905.6) was incu-
bated at pH 4.5 plus cysteine for 90 min at
37 C, followed by purification and ion spray
mass spectroscopy. (B) GILT catalyzed the re-
duction of cys- I at low pH. The cys- I pep-
tide incubated with purified human GILT (28.5
ng/ml) plus cysteine at pH 4.5, was isolated and
analyzed by mass spectroscopy. The appearance
of ionized species at 894 and 596 m/z, is indic-
ative of peptide reduction. (C) Insert showing
the dose dependent reduction of cys- I by pu-
rified GILT. The ratio of relative peak heights
for ionized m 2 fragments from the reduced  I
(894  m/z) and cys- I (954 m/z) peptides
present in the reaction mixture was calculated
as an indication of epitope reduction. Similar
results were obtained by analyzing the ionized
m 3 species at 596 and 636 m/z for the reduced
and oxidized peptides.
class II– and class I–restricted T cells recognizing this anti-
gen have been isolated from patients with metastatic mela-
nomas, leading to the proposal that select tyrosinase
epitopes may be useful for vaccine therapy (12, 30, 34). To
examine whether GILT facilitates the reductive processing
and presentation of endogenous tyrosinase in melanomas,
functional studies were conducted using human T cell lines
derived from patients. An epitope within tyrosinase, resi-
dues 56–70 has been shown to bind DR4 alleles with a
measurable affinity, and T cells recognizing this peptide
have been detected and isolated from multiple melanoma
patients (12, 30). The expression of GILT in tumor cells
significantly enhanced T cell responses to this immuno-
dominant DR4-restricted tyrosinase epitope (Fig. 6). Un-
like the Ig  I epitope, T cell recognition of this tyrosinase
epitope was not completely dependent on GILT expression
with reduced presentation detectable in the J3.DR4 tumor
lacking GILT. Activation of tyrosinase-specific T cells by
the SML2-mel tumor with low intracellular GILT, was also
reduced compared with J3.GILT.DR4 or peptide pulsed
professional APCs (data not shown). While differences in
the class II–restricted presentation of tyrosinase 56–70 were
detected using tumor cells with and without GILT, no
change was detected in the presentation of a class I A2–
restricted epitope from a distinct melanoma antigen gp100
(residue 209–217) using these same tumors (Fig. 6). There
are no cysteine residues within this class I–restricted pep-1274 Alterations in Antigen Presentation due to the Lack of GILT in Melanomas
essential for the processing of all tumor cell antigens, several
melanoma proteins under consideration for immunothera-
peutics, tyrosinase, gp-100, and Mart-1 contain a signifi-
cant number of cystine and cysteine residues. In addition,
at least two class I epitopes derived from tyrosinase have
been shown to be susceptible to spontaneous cysteinylation
which can influence recognition by patient CTL (34). Hu-
man CD4  T cells responsive to tyrosinase, including the
epitope 56–70 have been isolated from multiple melanoma
patients suggesting in vivo presentation of this antigen in
the context of MHC class II molecules (12, 30). Analysis of
several patients with tumor regression after surgery or im-
munotherapy revealed measurable levels of circulating
CD4  T cells reactive against tyrosinase 56–70, indicating
infiltrating APCs may play a role in T cell priming or acti-
vation (30). Studies here demonstrate that while APCs effi-
ciently displayed this peptide in the context of DR4, tumor
cell presentation of this epitope was reduced but could be
measurably enhanced with increased intracellular GILT
levels. Thus, the lack of GILT expression in melanomas
can alter the profile of peptides displayed to T cells.
Malignant cells may evade or avoid T cell surveillance
and destruction through alterations in the expression of dis-
tinct tumor antigens or disruptions in the pathways for
MHC-restricted presentation (36). In terms of the latter,
studies with a number of melanomas have demonstrated
the loss of cofactors such as TAP and the proteasome LMP
subunits, both necessary for epitope presentation by MHC
class I molecules (36, 37). In these tumors, the display of
antigenic epitopes bound to surface MHC class II mole-
cules may take on a more significant role in promoting im-
munological detection and memory. Yet, the expression of
surface class II molecules by melanomas does not always
correlate with enhanced immunological clearance or the
development of long-term immunity (1). T cell responses
to peptide–class II complexes displayed on melanomas are
significantly reduced compared with professional APCs
(11–13). Potential explanations include reduced costimula-
tory capacity of tumors (38, 39), defects in antigen presen-
tation (13), and reduced tumor cell responsiveness to cyto-
kines such as IFN-  (40). The lack of GILT production by
melanomas, as demonstrated here may in part explain the
limited role of class II molecules in promoting T cell re-
sponses specific for these tumors. Additional studies will be
necessary to definitely test whether the GILT expression al-
Figure 5. Absence of GILT in melanomas influences the hierarchy of
IgG epitope presentation by class II molecules. (A) J3.DR4 melanomas
failed to efficiently process and present the  I epitope from the antigen
human IgG, yet class II–restricted display of another peptide  II was de-
tected. (B) Presentation of the  I epitope was restored by transfection of
melanomas with GILT cDNA. For J3.GILT.DR4 cells, class II–restricted
presentation of the  II epitope was also enhanced nearly two- to three-
fold compared with tumors lacking GILT. (C) Frev, B lymphoblasts pref-
erentially present the immunodominant  I epitope in comparison to a
subdominant peptide  II. Cells were incubated with purified human IgG
for 3–18 h followed by coculture with T cells and quantitation of cyto-
kine activation. (D) GILT expression promotes the presentation of en-
dogenous  I epitopes. Transfected tumors expressing the IgG antigen,
J3.DR4-IgG and J3.GILT.DR4-IgG were cocultured with the  I- and
 II-specific T cells for 20–24 h at 37 C followed by quantitation of T cell
cytokine production.
Figure 6. Expression of GILT in melanomas enhances class II–
restricted presentation of an endogenous tyrosinase epitope. Human CD4 
T cells (clone HTL-T56) specific for tyrosinase 56–70 and HLA-DR4
were cultured with tumor cells J3.DR4, and J3.GILT.DR4 followed by
ELISPOT analysis to detect IFN-  production. A similar analysis was run
using J3.DR4 and J3.GILT.DR4 cells and the human CD8  T cells clone
G209 specific for gp100 (209–217). Results represent specific cytokine
production in response to tumor cells expressing tyrosinase with a correc-
tion for nonspecific T cell activation detected with presenting cells lack-
ing the test antigen. The mean number of spots detected in triplicate assays
plus the SD are indicated.1275 Haque et al.
ters T cell recognition and tumor clearance in vivo. Of the
class II  tumors analyzed, all retained expression of the es-
sential cofactors, invariant chain and DM which function
to facilitate peptide loading. Yet low or no GILT accumu-
lation was detectable in the human melanomas tested, and
only limited reductase activity induced after interferon
treatment, thus suggesting divergent gene regulation for
GILT and other conserved elements of the class II pathway
within these tumors.
The uncoupling of GILT and class II gene expression in
melanomas may contribute to tumor cell survival or induc-
tion of immune unresponsiveness. Professional APCs can
function as sentinels acquiring and cross-presenting shed
tumor antigens to prime and activate T cells. Studies have
shown that dendritic cells incubated in vitro with tumor-
derived peptides can also be used as vaccine reagents to
promote the activation of cytotoxic and helper T cell pop-
ulations in melanoma patients (41). The repertoire of
CD4  T cells primed can be influenced by APC expres-
sion of GILT, as in vivo T cell responses to select antigens
were reduced in animals lacking GILT after targeted gene
disruption (42). While tumor cell destruction is not abso-
lutely dependent on MHC class II protein expression (43),
studies have demonstrated direct T cell recognition of tu-
mor cell peptide–class II complexes (3, 11, 44). The ability
of melanomas to display altered peptides or a distinct hier-
archy of antigenic epitopes relative to APCs, may therefore
be important. For example, the presentation of cystein-
ylated peptides by class II  melanomas could be exploited
during the design of novel vaccine targets to boost tumor-
specific immunity. Yet, there may also be negative conse-
quences to the display of altered peptide ligands by MHC
molecules. Even subtle changes in the structure of peptide–
class II complexes have been shown to induce T cell an-
ergy or immunological unresponsiveness via changes in
TCR contacts and engagement (45). It has also been pro-
posed that epitope spreading and the induction of immune
responses to subdominant and cryptic antigenic epitopes
may be useful for induction of tumor immunity and over-
coming such unresponsiveness (41, 46). Indeed, in this
study melanoma cells were capable of presenting a sub-
dominant epitope to T cells despite their inability to dis-
play an established immunodominant peptide from the
same antigen. Clearly, the identification of differential anti-
gen processing pathways within tumors and professional
APCs, suggests such alternative strategies for promoting
immunity to tumors may be important.
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